These results imply that ABR, PREX1, DOCK2, and DOCK4 can function as tumor suppressors in NSCLC, while more specific data on tumor subgroups and the corresponding survival data are needed for confirmation. This evidence concerns the gene PREX1 and non-small cell lung carcinoma.